Original Article
TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program
N Engl J Med 2006; 355:241-250July 20, 2006
- Abstract
Background
Common polymorphisms of the transcription factor 7–like 2 gene (TCF7L2) have recently been associated with type 2 diabetes. We examined whether the two most strongly associated variants (rs12255372 and rs7903146) predict the progression to diabetes in persons with impaired glucose tolerance who were enrolled in the Diabetes Prevention Program, in which lifestyle intervention or treatment with metformin was compared with placebo.
Methods
We genotyped these variants in 3548 participants and performed Cox regression analysis using genotype, intervention, and their interactions as predictors. We assessed the effect of genotype on measures of insulin secretion and insulin sensitivity at baseline and at one year.
Results
Over an average period of three years, participants with the risk-conferring TT genotype at rs7903146 were more likely to have progression from impaired glucose tolerance to diabetes than were CC homozygotes (hazard ratio, 1.55; 95 percent confidence interval, 1.20 to 2.01; P<0.001). The effect of genotype was stronger in the placebo group (hazard ratio, 1.81; 95 percent confidence interval, 1.21 to 2.70; P=0.004) than in the metformin and lifestyle-intervention groups (hazard ratios, 1.62 and 1.15, respectively; P for the interaction between genotype and intervention not significant). The TT genotype was associated with decreased insulin secretion but not increased insulin resistance at baseline. Similar results were obtained for rs12255372.
Conclusions
Common variants in TCF7L2 seem to be associated with an increased risk of diabetes among persons with impaired glucose tolerance. The risk-conferring genotypes in TCF7L2 are associated with impaired beta-cell function but not with insulin resistance. (ClinicalTrials.gov number, NCT00004992.)
Media in This Article
Figure 1
Incidence of Diabetes According to Treatment Group and Genotype at Variant rs7903146.Figure 2
Effects of Genotype at rs7903146 on Insulin Secretion at Baseline as Measured by the Mean (±SE) Insulin:Glucose Ratio (Panel A) and the Corrected Insulin Response (Panel B).Article Activity
- Article
The risk of type 2 diabetes is strongly influenced by inheritance.1 Genetic susceptibility to the common form of type 2 diabetes appears polygenic — that is, it involves a number of variants, each with a modest effect on the risk of disease in an individual person.2 Despite important advances in understanding the genetic determinants of the relatively rare monogenic forms of diabetes,3 the pace of definitive identification of genes that increase the risk of common type 2 diabetes has been slow.
Recently, Grant and colleagues4 reported on the association of a common microsatellite (DG10S478) within intron 3 of the transcription factor 7–like 2 gene (TCF7L2) with type 2 diabetes in an Icelandic case–control sample and replicated this result in two additional case–control cohorts of white patients. The noncoding single-nucleotide polymorphisms rs12255372 and rs7903146 were in strong linkage disequilibrium with DG10S478 (r2=0.95 and r2=0.78, respectively) and showed similarly robust associations with type 2 diabetes (P<10−15). The authors recommended that these two single-nucleotide polymorphisms be genotyped in all attempts at replication.
Reproducibility of reported genetic associations is essential in complex human genetics, especially among populations of different races, ethnic backgrounds, and environmental exposures.5-8 Furthermore, the effect that these polymorphisms have on the risk of type 2 diabetes and on validated preventive interventions has not been prospectively ascertained. Finally, the pathophysiological mechanism by which variation in TCF7L2 might influence glycemic traits is not clear. Therefore, we genotyped the rs12255372 and rs7903146 variants in 3548 participants in the Diabetes Prevention Program (DPP) to try to confirm this association, to assess the effect of these variants on the lifestyle and pharmacologic interventions used in the DPP,9 and to explore the effect of these variants on insulin secretion, insulin sensitivity, or both.
Methods
The Diabetes Prevention Program
The DPP Research Group9 conducted a multicenter, randomized clinical trial from 1996 to 2001 at 27 centers in the United States. The institutional review board at each center approved the protocol, and all participants gave written informed consent. The trial was designed to test whether a lifestyle intervention or pharmacologic treatment with metformin would prevent or delay the development of diabetes in persons at increased risk for the disease.9,10 The DPP enrolled 3234 overweight persons in the United States without diabetes who had elevated plasma glucose concentrations after an overnight fast and impaired glucose tolerance. As compared with placebo, the lifestyle interventions and treatment with metformin reduced the incidence of diabetes by 58 percent (95 percent confidence interval, 48 to 66 percent) and 31 percent (95 percent confidence interval, 17 to 43 percent), respectively, over an average follow-up period of approximately three years.9 An additional group of 585 participants was treated with troglitazone, but this treatment was halted during the DPP trial owing to its toxic effects on the liver.10
Participants
The 3548 participants included in this study (92.9 percent of the participants in the DPP trial; 2994 subjects randomly assigned to placebo, lifestyle intervention, or metformin, plus 554 participants initially randomly assigned to troglitazone, in whom only quantitative traits were analyzed) each provided written informed consent for the genetic investigation. Of these participants, 66.8 percent were women, 56.4 percent white, 20.2 percent African American, 16.8 percent Hispanic, 4.3 percent Asian, and 2.4 percent American Indian, according to self-report. The mean (±SD) age was 51±11 years, and the mean body-mass index (BMI) (the weight in kilograms divided by the square of the height in meters) was 34.0±6.7. The development of diabetes was assessed on the basis of semiannual measurements of fasting plasma glucose concentrations and annual oral glucose-tolerance tests (with a 75-g oral glucose load).9,10
Genotyping
DNA was extracted from peripheral-blood leukocytes and quantitated with the use of PicoGreen analysis (Molecular Probes). Genotyping was performed by allele-specific primer extension of singleplex amplified products, with detection by matrix-assisted laser desorption–ionization time-of-flight mass spectroscopy on a Sequenom platform.11,12 The genotyping success rate was 99.3 percent, and the consensus rate (on the basis of 222 duplicate genotypes) was 99.1 percent. The allele frequencies for both single-nucleotide polymorphisms in each of the five races or ethnic groups were in Hardy–Weinberg equilibrium (P>0.05).
Quantitative Measures
Data from the baseline oral glucose-tolerance test were used to calculate two measures of insulin secretion13,14 and two measures of insulin sensitivity15,16 as previously described.17 We used glucose and insulin measured in conventional units (milligrams per deciliter and microunits per milliliter, respectively) unless otherwise specified. Measures of insulin secretion included the fasting insulin:glucose ratio, calculated by dividing (insulin at 30 minutes−insulin at 0 minutes) by (glucose at 30 minutes−glucose at 0 minutes), and the corrected insulin response, calculated by means of the following equation: (100×insulin at 30 minutes)÷[glucose at 30 minutes×(glucose at 30 minutes−70 mg per deciliter)]. Measures of insulin sensitivity included the reciprocal of the fasting insulin level and the insulin-sensitivity index, which is the reciprocal of insulin resistance according to the homeostasis model assessment16 and is calculated by the following equation: 22.5÷[fasting insulin×(fasting glucose÷18.01)]. We have previously shown that both measures of insulin secretion strongly correlate with each other, as do both measures of insulin sensitivity.17
Statistical Analysis
We examined Cox regression models according to genotype, intervention, and interactions between genotype and intervention as the independent variables predicting the incidence of diabetes. To test for interactions, we contrasted the likelihood of the model that included all two-way treatment and genotype interaction terms with the likelihood of the model without any interaction terms; the ratio has a chi-square distribution. If this was significant, we tested each interaction term with the use of the Wald test.18 Models were adjusted for risk factors for diabetes at enrollment. Because there was no evidence of differences between race or ethnic groups in the incidence of diabetes for any of the interventions, initial analyses of the effects of genotype on incidence were performed for all races and ethnic groups combined; they were also repeated only in populations that had similar allele frequencies (whites and African Americans together). No significant interaction between ethnicity and genotype was detected in any of our analyses. The population attributable risk was estimated with data from the placebo group for each ethnic group, calculated as follows: 1−(1÷[p2HRhom+2p(1−p)HRhet+(1−p)2]), where p is the risk-allele frequency, HRhom is the hazard ratio for homozygotes, and HRhet is the hazard ratio for heterozygotes.
For the quantitative trait analyses, baseline measures in the entire cohort (obtained in 3436 participants, including those randomly assigned to troglitazone) were log-transformed for non-normality and a generalized linear model was performed comparing values according to genotype. In cases in which log transformation did not result in a normal distribution, differences between means were compared with the use of a nonparametric Wilcoxon test. We further obtained an estimate of “composite beta-cell function” by adjusting baseline insulin secretion to insulin sensitivity through linear regression of log-transformed variables.17 For the one-year analyses, we focused on the insulin:glucose ratio as a measure of insulin secretion and the insulin-sensitivity index as a measure of insulin sensitivity, and we used a generalized linear model with interaction terms of genotype and treatment. Means were adjusted for baseline measures. Nominal two-sided P values are reported and were adjusted for multiple comparisons (three genotypic groups within each trait) with the use of the Holm procedure.19 Analyses were done with the use of SAS software, version 8.2 (SAS Institute).
Results
Distribution of Allele Frequencies
Baseline demographic and anthropomorphic characteristics are shown in Table 1Table 1
Baseline Characteristics of the Cohort According to Genotype at the rs12255372 and rs7903146 Variants.. For rs12255372, the frequency of the minor T allele in whites enrolled in the DPP (0.32) was similar to that previously reported in European populations.4 The frequency of minor alleles was similar in African Americans (0.31) but lower in Hispanics (0.23), Asians (0.14), and American Indians (0.05). Similar distributions were noted for rs7903146, with minor allele frequencies of 0.33 in whites, 0.31 in African Americans, 0.24 in Hispanics, 0.17 in Asians, and 0.12 in American Indians. Linkage disequilibrium between both variants was strong in people of European descent (D′=0.90, r2=0.78) but nearly absent in African Americans (D′=0.11, r2=0.01). Allele frequencies were similar across treatment groups.Incidence of Diabetes
Grant et al.4 identified the T alleles at both single-nucleotide polymorphisms as the risk variants. In the DPP, participants who were homozygous for the T allele at rs7903146 were more likely to have progression to diabetes than were those who were homozygous for the C allele (hazard ratio, 1.55; 95 percent confidence interval, 1.20 to 2.01; P<0.001). No excess risk was conferred by the heterozygous genotype (Table 2Table 2
Incidence of Diabetes According to Genotype at the rs12255372 and rs7903146 Variants.). The effect of the risk-conferring genotype was greatest in the placebo group (hazard ratio, 1.81; 95 percent confidence interval, 1.21 to 2.70; P=0.004) and less in the metformin group (hazard ratio, 1.62; 95 percent confidence interval, 1.03 to 2.54; P=0.04) and in the lifestyle-intervention group (hazard ratio, 1.15; 95 percent confidence interval, 0.68 to 1.94; P=0.60). In the placebo group, the incidence of diabetes for the TT, CT, and CC genotypes at rs7903146 was 18.5, 10.7, and 10.8 per 100 person-years, respectively (Figure 1Figure 1Incidence of Diabetes According to Treatment Group and Genotype at Variant rs7903146.). The results were similar for the risk-conferring TT genotype at rs12255372 as compared with the GG genotype, both in the overall group (hazard ratio, 1.53; 95 percent confidence interval, 1.17 to 2.01; P=0.002) and in the placebo group (hazard ratio, 1.81; 95 percent confidence interval, 1.19 to 2.75; P=0.005). Results for rs12255372 in the metformin and lifestyle-intervention groups were similar to those for rs7903146 but not significant (hazard ratio, 1.45 and 1.24, respectively; 95 percent confidence intervals, 0.90 to 2.35 and 0.73 to 2.12; P=0.13 and P=0.43).Although the effect of genotype at both single-nucleotide polymorphisms was stronger in the placebo group than in the metformin and lifestyle-intervention groups, there were no significant interactions between genotype and intervention at either locus. Similarly, there were no significant interactions between genotype and race or ethnic group or between genotype and BMI on diabetes incidence (Table 2). When we restricted our analysis to the populations with similar allele frequencies, the effect of the TT genotype, as compared with the CC genotype, at rs7903146 on the risk of diabetes was indistinguishable from the overall result (hazard ratio, 1.63; 95 percent confidence interval, 1.17 to 2.27; P=0.004 in 2276 whites and African Americans together); we found similar results for rs12255372.
Quantitative Measures
We examined whether the risk allele at either single-nucleotide polymorphism affected quantitative glycemic traits. At baseline, carriers of the T allele at rs7903146 had significantly lower levels of insulin secretion than did CC homozygotes, as measured by both the insulin:glucose ratio and the corrected insulin response (Figure 2Figure 2
Effects of Genotype at rs7903146 on Insulin Secretion at Baseline as Measured by the Mean (±SE) Insulin:Glucose Ratio (Panel A) and the Corrected Insulin Response (Panel B).). Similar results were obtained for the T allele at rs12255372.Surprisingly, two mean baseline measures of insulin sensitivity were significantly higher in the presence of T alleles and in proportion to the number of T alleles (Figure 3Figure 3
Insulin Secretion and Insulin Sensitivity at Baseline for Each Genotype at rs7903146.). Composite beta-cell function seemed to be impaired in TT homozygotes, as indicated by a shift in the regression curve downward and to the left (Figure 3). The greater mean insulin sensitivity in carriers of T alleles at rs7903146 correlated with a concomitant lower mean BMI and waist circumference at baseline and persisted after adjustment for these traits; a similar trend was noted for rs12255372 (Table 1).Given these results of quantitative traits, we adjusted our models of the incidence of diabetes for the presence of known risk factors. Initial adjustment for age and BMI at baseline did not alter the results; full adjustment for sex and age, BMI, waist circumference, and the fasting plasma glucose concentration at baseline reduced the hazard ratios slightly as compared with homozygous genotypes, but they remained significant (hazard ratio for the TT genotype as compared with the CC genotype at rs7903146, 1.39; 95 percent confidence interval, 1.06 to 1.82; P=0.02). When the influence of covariates was assessed with the inclusion of interaction terms in the model, only waist circumference showed a nominally significant interaction with genotype. Including the baseline insulin:glucose ratio in the model as a measure of insulin secretion also minimally decreased the observed effect (hazard ratio for the TT genotype as compared with the CC genotype at rs7903146, 1.41; 95 percent confidence interval, 1.08 to 1.83; P=0.01). Similar results were obtained for rs12255372.
At one year from baseline, we detected no significant effects of genotype on the changes in any of the insulin-secretion or insulin-sensitivity indexes associated with the three interventions,17,20 consistent with the absence of interactions between genotype and treatment group.
Discussion
Inconsistent reproducibility has been a vexing problem for genetic association studies in complex diseases.6,7,21 False positive reports of association, false negative attempts at replication, and genetic heterogeneity often complicate the picture, and thus a true genetic association usually emerges only after carefully conducted, large-scale association studies confirm the original report.8
A limited number of common genetic variants meet that high standard in type 2 diabetes.22 In most cases, the genotypic risk is modest (1.15 to 1.25), requiring very large sample sizes for detection. The recent identification of a common allele in the TCF7L2 gene that increases the risk of type 2 diabetes by approximately 1.45 in heterozygotes and 2.41 in homozygotes4 is therefore quite provocative. Despite these significant results in a cross-sectional study,4 it was essential to replicate this genetic association in other cohorts and to do so prospectively. In addition, our evaluation of a potential mechanism by which the risk of diabetes is increased and the determination of whether these variants cause differential responses to validated preventive strategies represent important next steps in exploring the association.
The DPP is a unique study in which to carry out such analyses. The large sample size and the cohort of several races and ethnic groups, reflecting the diversity of the U.S. population with type 2 diabetes, make it possible to test the role of genetic variants in different races or ethnic groups, even if they confer only modest risk. The DPP study is different from other large observational studies23 because of its interventional design and exclusive enrollment of overweight or obese persons with elevated fasting plasma glucose concentrations and impaired glucose tolerance, which indicate a high risk of diabetes at baseline.
Our data indicate that the risk alleles in rs7903146 and rs12255372 predict the risk of diabetes prospectively, beyond that conferred by the clinical risk factors reflected by the DPP eligibility criteria. The genotypic relative risk may differ slightly from the odds ratio documented by Grant et al.4 owing to a different study design, an overestimate of the initial finding,6 population heterogeneity in the DPP, various degrees of linkage disequilibrium between the DG10S478 microsatellite and the single-nucleotide polymorphisms evaluated here, or our limited temporal window (three years on average) for the clinical transition from impaired glucose tolerance to diabetes. The size of the effect seems robust for a sample of this size; given the higher probability conferred by the initial report, our finding is a strong confirmation of the original genetic association.
Grant and coworkers4 exhaustively assessed coding variation in whites by a variety of deep resequencing methods in the region, suggesting that other functional variants in this gene are unlikely to have been missed. In addition to rs12255372 and rs7903146, other single-nucleotide polymorphisms in linkage disequilibrium with them were also strongly associated with diabetes. Which of these single-nucleotide polymorphisms is responsible for the observed association requires further study in adequately powered samples. In particular, the absence of linkage disequilibrium between rs7903146 and rs12255372 in African Americans may help distinguish whether one of the two single-nucleotide polymorphisms (or the haplotype formed by the risk alleles at both loci) is the sole source of the association signal; we could not make this distinction after initial exploratory analyses in our data set, perhaps because of inadequate sample size. Given their allele frequencies and assuming an overall genotypic relative risk of 1.54 (Table 2) and diabetes prevalence of 10 percent among African Americans, we estimate that the enrollment of approximately 1400 persons of African ancestry would be necessary for the case–control study to have 80 percent power (with a P value of less than 0.05 considered to indicate statistical significance) to distinguish between rs7903146 and rs12255372 as the source of the association. Sample sizes at least twice as large would be needed if one intended to detect a signal arising solely from the haplotype formed by the minor alleles at both loci.
We studied the TCF7L2 single-nucleotide polymorphisms in nonwhite populations. Subgroup analysis according to race or ethnic group showed similar effect sizes at this locus, but these effect sizes were not individually significant, possibly because of inadequate sample size. However, we cannot rule out effects of genotype on risk that were specific to race or ethnic group; with the results we have obtained here, a cohort of more than 20,000 persons would be needed to detect an interaction between genotype and African-American ethnicity, at a nominal (unadjusted) P value of less than 0.05. Similarly, our sample size may not have been sufficient to detect a significant effect of the heterozygous genotype on the risk of diabetes. Nevertheless, the results of the report by Grant et al.4 and our findings of a specific effect of a single copy of the T allele on quantitative glycemic traits suggest that heterozygosity at this locus may have phenotypic consequences.
The original study speculated that genetic variation in TCF7L2 might impair the expression of glucagon-like peptide 1 in enteroendocrine cells, possibly by interfering with β-catenin–mediated transcriptional activation of its gene GCG.24 Our finding that insulin secretion is decreased in carriers of the risk-conferring genotype, which is consistent with an increased incidence of diabetes, lends indirect support to this model. However, it is not readily apparent how rs12255372 and rs7903146, which lie in short interspersed repeat elements approximately 41 kb upstream and 9 kb downstream, respectively, of exon 4 in TCF7L2, might affect TCF7L2 expression or the function of its protein product. Fine mapping of the association signal and directed functional studies should help determine the molecular consequences of genetic variation at this locus.
The enhanced insulin sensitivity (and the lower BMI and smaller waist circumference) in carriers of the T allele at both single-nucleotide polymorphisms was unexpected and may be an artifact of our requirement that patients have high-risk characteristics for diabetes at enrollment. Specifically, if the T allele leads to decreased insulin secretion and a higher risk of diabetes, subjects with additional insulin resistance would be more likely to have diabetes at baseline (all other factors being equal), precluding their enrollment in this trial. Conversely, at-risk participants carrying the T allele may not have had diabetes at the time of enrollment because of enhanced insulin sensitivity owing to other genetic or environmental factors. In either case, our results strongly suggest that these variants do not cause insulin resistance in persons with impaired glucose tolerance and support the notion that variants in TCF7L2 lead to diabetes by means of defects in insulin secretion. Like KCNJ11, TCF7L2 seems to be a diabetes-associated gene in which common polymorphisms primarily affect the beta cell.23,25,26
Finally, we did not detect significant interactions between genotypes at either single-nucleotide polymorphism and the DPP interventions. The absence of an effect may not be surprising, since these interventions succeeded primarily by improving insulin sensitivity17 and these variants affect insulin secretion. However, we did not observe any effect of genotype at these loci in the lifestyle-intervention group, raising the possibility that a behavioral intervention can mitigate the risk conferred by genetic background. Conversely, the intervention groups may have been underpowered for these analyses. Whether the response to drugs designed to improve insulin secretion (e.g., sulfonylureas, meglitinides, or incretins) will be affected by these common variants requires specific testing in pharmacogenetic trials.
In summary, our results from this large prospective study confirm and extend the finding that the transcription factor gene TCF7L2 is associated with susceptibility to type 2 diabetes. Further understanding of the mechanisms by which variation in this gene affects glucose homeostasis may provide new insights into the molecular basis of diabetes and opportunities for more targeted interventions for prevention and therapy.
Supported by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Office of Research on Minority Health, the National Institute of Child Health and Human Development, the Office of Women's Health, and the National Institute on Aging; the Indian Health Service; the Centers for Disease Control and Prevention; the American Diabetes Association; Bristol-Myers Squibb; and Parke-Davis; an NIH grant (R01DK072041-01, to Drs. Altshuler, Florez, Pollin, and Shuldiner); and in part by the Intramural Research Program of the NIDDK. Many of the clinical centers were supported by the General Clinical Research Center Program, National Center for Research Resources. The clinical centers and the coordinating center were supported by the NIDDK through a cooperative agreement, except the Southwestern American Indian Centers, which were supported directly by the NIDDK and the Indian Health Service. Dr. Florez is supported by an NIH Research Career Award (K23 DK65978-03).
Dr. Shuldiner reports having received consulting fees from Merck, Sanofi-Aventis, and Sensors for Medicine, as well as lecture fees from Sanofi-Aventis. Dr. Altshuler reports having received consulting fees from Rosetta Inpharmatics (a subsidiary of Merck) and serving on the advisory board of Medical Portfolio Management. No other potential conflict of interest relevant to this article was reported.
We are indebted to Santica Marcovina and Greg Strylewicz for their careful processing of the DNA samples; to Mark Daly, Noël Burt, and our colleagues at the Broad Institute Genetic Analysis Platform for their assistance; and to the participants of the DPP for their commitment and dedication.
Source Information
From the Diabetes Prevention Program Outcomes Study Coordinating Center, George Washington University, Rockville, Md.
Address reprint requests to Dr. Florez at the Diabetes Prevention Program Coordinating Center, the Biostatistics Center, George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852, or at dppmail@biostat.bsc.gwu.edu.
- References
References
1
Barroso I . Genetics of type 2 diabetes. Diabet Med 2005;22:517-535
CrossRef | Web of Science | Medline2
Florez JC ,Hirschhorn JN ,Altshuler D . The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003;4:257-291
CrossRef | Web of Science | Medline3
Fajans SS ,Bell GI ,Polonsky KS . Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-980
Full Text | Web of Science | Medline4
Grant SFA ,Thorleifsson G ,Reynisdottir I , et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323
CrossRef | Web of Science | Medline5
Freely associating. Nat Genet 1999;22:1-2
CrossRef | Web of Science | Medline6
Ioannidis JP ,Ntzani EE ,Trikalinos TA ,Contopoulos-Ioannidis DG . Replication validity of genetic association studies. Nat Genet 2001;29:306-309
CrossRef | Web of Science | Medline7
Lohmueller K ,Pearce CL ,Pike M ,Lander ES ,Hirschhorn JN . Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-182
CrossRef | Web of Science | Medline8
Hattersley AT ,McCarthy MI . What makes a good genetic association study? Lancet 2005;366:1315-1323
CrossRef | Web of Science | Medline9
Diabetes Prevention Program Research Group
Full Text | Web of Science | Medline10
Diabetes Prevention Program Research Group
CrossRef | Web of Science | Medline11
Gabriel SB ,Schaffner SF ,Nguyen H , et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229
CrossRef | Web of Science | Medline12
Tang K ,Fu DJ ,Julien D ,Braun A ,Cantor CR ,Koster H . Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci U S A 1999;96:10016-10020
CrossRef | Web of Science | Medline13
Sluiter WJ ,Erkelens DW ,Reitsma WD ,Doorenbos H . Glucose tolerance and insulin release, a mathematical approach. I. Assay of the β-cell response after oral glucose loading. Diabetes 1976;25:241-244
CrossRef | Web of Science | Medline14
Phillips DI ,Clark PM ,Hales CN ,Osmond C . Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994;11:286-292
CrossRef | Web of Science | Medline15
Hanson RL ,Pratley RE ,Bogardus C , et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190-198
Web of Science | Medline16
Matthews DR ,Hosker JP ,Rudenski AS ,Naylor BA ,Treacher DF ,Turner RC . Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
CrossRef | Web of Science | Medline17
The Diabetes Prevention Program Research Group
CrossRef | Web of Science | Medline18
Greenberg RS ,Kleinbaum DG . Mathematical modeling strategies for the analysis of epidemiologic research. Annu Rev Public Health 1985;6:223-245
CrossRef | Web of Science | Medline19
Holm S . A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70
Web of Science20
The Diabetes Prevention Program Research Group
CrossRef | Web of Science | Medline21
Hirschhorn JN ,Lohmueller K ,Byrne E ,Hirschhorn K . A comprehensive review of genetic association studies. Genet Med 2002;4:45-61
CrossRef | Web of Science | Medline22
O'Rahilly S ,Barroso I ,Wareham NJ . Genetic factors in type 2 diabetes: the end of the beginning? Science 2005;307:370-373
CrossRef | Web of Science | Medline23
Lyssenko V ,Almgren P ,Anevski D , et al. Genetic prediction of future type 2 diabetes. PLoS Med 2005;2:e345-e345
CrossRef | Web of Science | Medline24
Yi F ,Brubaker PL ,Jin T . TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β. J Biol Chem 2005;280:1457-1464
CrossRef | Web of Science | Medline25
Nielsen E-MD ,Hansen L ,Carstensen B , et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003;52:573-577
CrossRef | Web of Science | Medline26
Florez JC ,Burtt N ,de Bakker PIW , et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004;53:1360-1368
CrossRef | Web of Science | Medline
- Citing Articles (185)
Citing Articles
1
Bin Liu, Hui-Ming Lv, Li-Nan Li, Lei Xia, Hong-Xiu Zhang, Ya-Juan Zhang, Lei Lei. (2012) Common variants of transcription factor 7-like 2 (TCF7L2) are associated with reduced insulin secretion in women with polycystic ovary syndrome. Gynecological Endocrinology1-4
CrossRef2
Mathew J. Gregoski, Vernon A. Barnes, Martha S. Tingen, Yanbin Dong, Haidong Zhu, Frank A. Treiber. (2012) Differential Impact of Stress Reduction Programs upon Ambulatory Blood Pressure among African American Adolescents: Influences of Endothelin-1 Gene and Chronic Stress Exposure. International Journal of Hypertension 2012, 1-12
CrossRef3
Pablo Perez-Martinez, Antonio Garcia-Rios, Javier Delgado-Lista, Francisco Perez-Jimenez, Jose Lopez-Miranda. (2012) Metabolic syndrome: Evidences for a personalized nutrition. Molecular Nutrition & Food Research 56:1, 67-76
CrossRef4
Hong Qiao, Xuelong Zhang, Xuedan Zhao, Yanling Zhao, Lidan Xu, Haiming Sun, Songbin Fu. (2012) Genetic variants of TCF7L2 are associated with type 2 diabetes in a northeastern Chinese population. Gene
CrossRef5
Angharad R. Morgan. (2011) Determining Genetic Risk Factors for Pediatric Type 2 Diabetes. Current Diabetes Reports
CrossRef6
Matti Uusitupa, Jaakko Tuomilehto. (2011) Destiny in your own hands – Does a positive family history matter in the prevention of type 2 diabetes?. Primary Care Diabetes 5:4, 213-214
CrossRef7
Lei Chen, Dianna J. Magliano, Paul Z. Zimmet. (2011) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature Reviews Endocrinology
CrossRef8
Margarida C. Lopes, Eleftheria Zeggini, Kalliope Panoutsopoulou. (2011) Review: Do genome-wide association scans have potential for translation?. Clinical Chemistry and Laboratory Medicine---
CrossRef9
Hakon Hakonarson, Struan F. A. Grant. (2011) Genome-wide association studies (GWAS): impact on elucidating the aetiology of diabetes. Diabetes/Metabolism Research and Reviews 27:7, 685-696
CrossRef10
Hyun-Jung Cho, Soo-Youn Lee, Youn-Gyoon Kim, Soo-Yeon Oh, Jong-Won Kim, Woo-Seong Huh, Jae-Wook Ko, Hyung-Gun Kim. (2011) Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population. Clinica Chimica Acta 412:19-20, 1831-1834
CrossRef11
Laura E. Martínez-Gómez, Miguel Cruz, Gabriela A. Martínez-Nava, Vicente Madrid-Marina, Esteban Parra, Jaime García-Mena, Mónica Espinoza-Rojo, Barbara I. Estrada-Velasco, Luis F. Piza-Roman, Penelope Aguilera, Ana I. Burguete-García. (2011) A Replication Study of the IRS1, CAPN10, TCF7L2, and PPARG Gene Polymorphisms Associated with Type 2 Diabetes in Two Different Populations of Mexico. Annals of Human Genetics 75:5, 612-620
CrossRef12
Monika Buraczynska, Andrzej Swatowski, Dorota Markowska-Gosik, Agata Kuczmaszewska, Andrzej Ksiazek. (2011) Transcription factor 7-like 2 (TCF7L2) gene polymorphism and complication/comorbidity profile in type 2 diabetes patients. Diabetes Research and Clinical Practice 93:3, 390-395
CrossRef13
(2011) Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia 54:9, 2272-2282
CrossRef14
Silke A. Schäfer, Fausto Machicao, Andreas Fritsche, Hans-Ulrich Häring, Konstantinos Kantartzis. (2011) New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Research and Clinical Practice 93, S9-S24
CrossRef15
Miguel Klünder-Klünder, María Aurora Mejía-Benitez, Samuel Flores-Huerta, Ana I. Burguete-García, Jaime García-Mena, Miguel Cruz. (2011) rs12255372 Variant of TCF7L2 Gene Is Protective for Obesity in Mexican Children. Archives of Medical Research 42:6, 495-501
CrossRef16
Gaya Thanabalasingham, Anna L Gloyn, Katharine R Owen. (2011) Genome-wide association studies of Type 2 diabetes: are these ready to make an impact in the clinic?. Diabetes Management 1:4, 379-387
CrossRef17
Paul E. Drawz, John R. Sedor. (2011) The genetics of common kidney disease: a pathway toward clinical relevance. Nature Reviews Nephrology 7:8, 458-468
CrossRef18
Maria I. Vazquez-Roque, Michael Camilleri, Adrian Vella, Paula Carlson, Jeanette Laugen, Alan R. Zinsmeister. (2011) Association of TCF7L2 Allelic Variations with Gastric Function, Satiation, and GLP-1 Levels. Clinical and Translational Science 4:3, 183-187
CrossRef19
Christian Herder, Michael Roden. (2011) Genetics of type 2 diabetes: pathophysiologic and clinical relevance. European Journal of Clinical Investigation 41:6, 679-692
CrossRef20
Paula Carrasco Espí, Jesús Rico Sanz, Carolina Ortega Azorín, José Ignacio González Arráez, Salvador Ruiz de la Fuente, Eva María Asensio Márquez, Ramón Estruch Riba, Dolores Corella Piquer. (2011) Consistente asociación del polimorfismo rs7903146 en el gen TCF7L2 con mayor riesgo de diabetes en población mediterránea española. Clínica e Investigación en Arteriosclerosis 23:3, 125-132
CrossRef21
Jaewook Yang, Ian I. Hutchinson, Tariq Shah, David I. Min. (2011) Genetic and Clinical Risk Factors of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients. Transplantation 91:10, 1114-1119
CrossRef22
V Radha, S Kanthimathi, V Mohan. (2011) Genetics of Type 2 diabetes in Asian Indians. Diabetes Management 1:3, 309-324
CrossRef23
Catherine M. Phillips, Louisa Goumidi, Sandrine Bertrais, Martyn R. Field, Ross McManus, Serge Hercberg, Denis Lairon, Richard Planells, Helen M. Roche. (2011) Dietary saturated fat, gender and genetic variation at the TCF7L2 locus predict the development of metabolic syndrome. The Journal of Nutritional Biochemistry
CrossRef24
Kalliopi I. Pappa, Maria Gazouli, Konstantinos Economou, George Daskalakis, Eleni Anastasiou, Nicholas P. Anagnou, Aristides Antsaklis. (2011) Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population. Gynecological Endocrinology 27:4, 267-272
CrossRef25
Matheni Sathananthan, Adrian Vella. 2011. Is there a Role for Incretin-Based Therapy in Combination with Insulin?. , 91-95.
CrossRef26
I. Hadj Ali, E. Adberrahim, K. Ben Abdelghani, S. Barbouch, N. Mchirgui, K. Khiari, M. Chérif, M. Ounissi, N. Ben Romhane, N. Ben Abdallah, T. Ben Abdallah, H. Ben Maiz, A. Khedher. (2011) Incidence and Risk Factors for Post–Renal Transplant Diabetes Mellitus. Transplantation Proceedings 43:2, 568-571
CrossRef27
A. Räkel, A.D. Karelis. (2011) New-onset diabetes after transplantation: Risk factors and clinical impact. Diabetes & Metabolism 37:1, 1-14
CrossRef28
Laura P. Svetkey, Emily L. Harris, Eden Martin, William M. Vollmer, Gayle T. Meltesen, Vincent Ricchiuti, Gordon Williams, Lawrence J. Appel, George A. Bray, Thomas J. Moore, Michelle P. Winn, Paul R. Conlin. (2011) Modulation of the BP Response to Diet by Genes in the Renin–Angiotensin System and the Adrenergic Nervous System. American Journal of Hypertension 24:2, 209-217
CrossRef29
Kyong Soo Park. (2011) Sulwon Lecture 2009: The Search for Genetic Risk Factors of Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 35:1, 12
CrossRef30
Andreas Holstein, Michael Hahn, Antje Körner, Michael Stumvoll, Peter Kovacs. (2011) TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Medical Genetics 12:1, 30
CrossRef31
Eleanor R Grimm, Nanette I Steinle. (2011) Genetics of eating behavior: established and emerging concepts. Nutrition Reviews 69:1, 52-60
CrossRef32
Melissa C Smart-Halajko, Alyson Kelley-Hedgepeth, Maria Montefusco, Jackie A Cooper, Alan Kopin, Jeanne M McCaffery, Ashok Balasubramanyam, Henry J Pownall, David M Nathan, Inga Peter, Philippa J Talmud, Gordon S Huggins, . (2011) ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. BMC Medical Genetics 12:1, 89
CrossRef33
Lin T. Guey, Jasmina Kravic, Olle Melander, Noël P. Burtt, Jason M. Laramie, Valeriya Lyssenko, Anna Jonsson, Eero Lindholm, Tiinamaija Tuomi, Bo Isomaa, Peter Nilsson, Peter Almgren, Sekar Kathiresan, Leif Groop, Albert B. Seymour, David Altshuler, Benjamin F. Voight. (2011) Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare variants. Genetic Epidemiologyn/a-n/a
CrossRef34
A. P. Gjesing, L. L. Kjems, M. A. Vestmar, N. Grarup, A. Linneberg, C. F. Deacon, J. J. Holst, O. Pedersen, T. Hansen. (2011) Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test. Diabetologia 54:1, 103-110
CrossRef35
Z. Schroner, M. Javorsky, R. Tkacova, L. Klimcakova, M. Dobrikova, V. Habalova, M. Kozarova, J. Zidzik, M. Rudikova, I. Tkac. (2011) Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 13:1, 89-91
CrossRef36
J. Delgado-Lista, P. Perez-Martinez, A. García-Rios, C.M. Phillips, C.M. Williams, H.L. Gulseth, O. Helal, E.E. Blaak, B. Kiec-Wilk, S. Basu, C.A. Drevon, C. Defoort, W.H. Saris, I. Wybranska, U. Riserus, J.A. Lovegrove, H.M. Roche, J. Lopez-Miranda. (2011) Pleiotropic effects of TCF7L2 gene variants and its modulation in the metabolic syndrome: From the LIPGENE study. Atherosclerosis 214:1, 110-116
CrossRef37
Virginia Boccardi, Immacolata Ambrosino, Michela Papa, Daniela Fiore, Maria Rosaria Rizzo, Giuseppe Paolisso, Michelangela Barbieri. (2010) Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity. European Journal of Human Genetics 18:12, 1333-1338
CrossRef38
Ola Hansson, Yuedan Zhou, Erik Renström, Peter Osmark. (2010) Molecular Function of TCF7L2: Consequences of TCF7L2 Splicing for Molecular Function and Risk for Type 2 Diabetes. Current Diabetes Reports 10:6, 444-451
CrossRef39
Niels Grarup, Thomas Sparsø, Torben Hansen. (2010) Physiologic Characterization of Type 2 Diabetes–Related Loci. Current Diabetes Reports 10:6, 485-497
CrossRef40
P. W. Franks, J. A. Nettleton. (2010) Invited Commentary: Gene x Lifestyle Interactions and Complex Disease Traits--Inferring Cause and Effect From Observational Data, Sine Qua Non. American Journal of Epidemiology 172:9, 992-997
CrossRef41
J. Zhao, J. Schug, M. Li, K. H. Kaestner, S. F. A. Grant. (2010) Disease-associated loci are significantly over-represented among genes bound by transcription factor 7-like 2 (TCF7L2) in vivo. Diabetologia 53:11, 2340-2346
CrossRef42
Liana K. Billings, Jose C. Florez. (2010) The genetics of type 2 diabetes: what have we learned from GWAS?. Annals of the New York Academy of Sciences 1212:1, 59-77
CrossRef43
K. Müssig, H. Staiger, F. Machicao, H.-U. Häring, A. Fritsche. (2010) Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 53:11, 2289-2297
CrossRef44
B. Burns, K. Schmidt, S. R. Williams, S. Kim, S. Girirajan, S. H. Elsea. (2010) Rai1 haploinsufficiency causes reduced Bdnf expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome. Human Molecular Genetics 19:20, 4026-4042
CrossRef45
Toshikazu Araoka, Hideharu Abe, Tatsuya Tominaga, Akira Mima, Takeshi Matsubara, Taichi Murakami, Seiji Kishi, Kojiro Nagai, Toshio Doi. (2010) Transcription factor 7-like 2 (TCF7L2) regulates activin receptor-like kinase 1 (ALK1)/Smad1 pathway for development of diabetic nephropathy. Molecules and Cells 30:3, 209-218
CrossRef46
V. A. Potapov, M. N. Shamkhalova, S. A. Smetanina, L. N. Bel’chikova, L. A. Suplotova, M. V. Shestakova, V. V. Nosikov. (2010) TCF7L2 rs12255372 and SLC30A8 rs13266634 confer susceptibility to type 2 diabetes in a Russian population. Russian Journal of Genetics 46:8, 1001-1008
CrossRef47
2010. Diagnosis and Classification of Diabetes. , 9-15.
CrossRef48
Mazen Alsahli, John E. Gerich. 2010. Abnormalities of Insulin Secretion and β-Cell Defects in Type 2 Diabetes. , 160-173.
CrossRef49
Martine Vaxillaire, Philippe Froguel. 2010. The Genetics of Type 2 Diabetes: From Candidate Gene Biology to Genome-Wide Studies. , 191-214.
CrossRef50
Yu Yan, Kari E. North, Gerardo Heiss, Ronald Klein, Cynthia J. Girman, Ethan M. Lange, James S. Pankow, Frederick L. Brancati, Eric Boerwinkle. (2010) Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of impaired fasting glucose in African American and Caucasian adults: the atherosclerosis risk in communities (ARIC) study. Diabetes/Metabolism Research and Reviews 26:5, 371-377
CrossRef51
Galina Smushkin, Adrian Vella. (2010) Genetics of type 2 diabetes. Current Opinion in Clinical Nutrition and Metabolic Care 13:4, 471-477
CrossRef52
Michael F. Greene, Caren G. Solomon, Stephanie L. Lee, Robert A. Peterfreund. 2010. Diabetes Mellitus in Pregnancy. , 293-321.
CrossRef53
Dima L. Diab, David A. D’Alessio. (2010) The Contribution of Enteroinsular Hormones to the Pathogenesis of Type 2 Diabetes Mellitus. Current Diabetes Reports 10:3, 192-198
CrossRef54
C. Herder. (2010) Genetische Studien zum Typ-2-Diabetes. Der Diabetologe 6:3, 203-209
CrossRef55
B. M. Shields, R. M. Freathy, A. T. Hattersley. (2010) Genetic influences on the association between fetal growth and susceptibility to type 2 diabetes. Journal of Developmental Origins of Health and Disease 1:02, 96
CrossRef56
S.-M. Ruchat, T. Rankinen, S. J. Weisnagel, T. Rice, D. C. Rao, R. N. Bergman, C. Bouchard, L. Pérusse. (2010) Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study. Diabetologia 53:4, 679-689
CrossRef57
Paul E. Drawz, John R. Sedor. (2010) Translating Associations Between Common Kidney Diseases and Genetic Variation Into the Clinic. Seminars in Nephrology 30:2, 195-202
CrossRef58
M Yu, X-J Xu, J-Y Yin, J Wu, X Chen, Z-C Gong, H-Y Ren, Q Huang, F-F Sheng, H-H Zhou, Z-Q Liu. (2010) KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) Polymorphisms Affect Therapeutic Efficacy of Repaglinide in Chinese Patients With Type 2 Diabetes. Clinical Pharmacology & Therapeutics 87:3, 330-335
CrossRef59
Barbara Szepietowska, Dariusz Moczulski, Natalia Wawrusiewicz-Kurylonek, Wladyslaw Grzeszczak, Maria Gorska, Malgorzata Szelachowska. (2010) Transcription factor 7-like 2-gene polymorphism is related to fasting C peptide in latent autoimmune diabetes in adults (LADA). Acta Diabetologica 47:1, 83-86
CrossRef60
Jane P. F Bai, Lawrence J Lesko, Gilbert J Burckart. (2010) Understanding the Genetic Basis for Adverse Drug Effects: The Calcineurin Inhibitors. Pharmacotherapy 30:2, 195-209
CrossRef61
K. M. Venkat Narayan, David F. Williamson. (2010) Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community. Journal of General Internal Medicine 25:2, 154-157
CrossRef62
Karani S. Vimaleswaran, Ruth J.F. Loos. (2010) Progress in the genetics of common obesity and type 2 diabetes. Expert Reviews in Molecular Medicine 12,
CrossRef63
N Maneka G De Silva, Timothy M Frayling. (2010) Novel biological insights emerging from genetic studies of type 2 diabetes and related metabolic traits. Current Opinion in Lipidology 21:1, 44-50
CrossRef64
Lu Qi, Jun Liang. (2010) Interactions between genetic factors that predict diabetes and dietary factors that ultimately impact on risk of diabetes. Current Opinion in Lipidology 21:1, 31-37
CrossRef65
Yi-Cheng Chang, Yen-Feng Chiu, Larry Low-Tone Ho, Chih-Tai Ting, Kuang-Chung Shih, J. David Curb, Yii-Der Ida Chen, Hung-Yuan Li, Lee-Ming Chuang. (2010) TCF7L2 genetic variants and progression to diabetes in the Chinese population: pleiotropic effects on insulin secretion and insulin resistance. Journal of Molecular Medicine 88:2, 183-192
CrossRef66
Sandra W. K. De Kort, Dennis O. Mook-Kanamori, Vincent W. V. Jaddoe, Anita C. S. Hokken-Koelega. (2010) Interactions between TCF7L2 genotype and growth hormone-induced changes in glucose homeostasis in small for gestational age children. Clinical Endocrinology 72:1, 47-52
CrossRef67
Massimo Motta, Ettore Bennati, Elisabeth Cardillo, Laura Ferlito, Michela Passamonte, Marco Vacante, Mariano Malaguarnera. (2010) A combination of glycosylated hemoglobin, impaired fasting glucose and waist circumference is effective in screening for individuals at risk for future type 2 diabetes. Archives of Gerontology and Geriatrics 50:1, 105-109
CrossRef68
Pei Xu, Yena Che, Yunxia Cao, XiaoKe Wu, Haixiang Sun, Fengjing Liang, Jing Sun, Lu Ke, Long Yi, Yong Wang. (2010) Polymorphisms of TCF7L2 and HHEX genes in Chinese women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics 27:1, 23-28
CrossRef69
Syann Lee, Charlotte E. Lee, Carol F. Elias, Joel K. Elmquist. (2009) Expression of the diabetes-associated gene TCF7L2 in adult mouse brain. The Journal of Comparative Neurology 517:6, 925-939
CrossRef70
Viktor A. Potapov, Dimitry A. Chistiakov, Minara S. Shamkhalova, Marina V. Shestakova, Valery V. Nosikov. (2009) TCF7L2 rs12255372 and SLC30A8 rs13266634 confer susceptibility to type 2 diabetes in a Russian population. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 3:4, 219-223
CrossRef71
R. W. Grant, M. Hivert, J. C. Pandiscio, J. C. Florez, D. M. Nathan, J. B. Meigs. (2009) The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia 52:11, 2299-2305
CrossRef72
A. L. Gloyn. (2009) RD Lawrence Lecture 2009 Old genes, new tricks: learning about blood glucose regulation from naturally occurring genetic variation in humans. Diabetic Medicine 26:11, 1083-1089
CrossRef73
Keynoosh Khalooghi, Saeid Hashemi, Nahid Mehraban, Parvin Amiri, Javad Tavakkoly Bazzaz, Bagher Larijani, Mahsa M. Amoli. (2009) In vitro modulation of TCF7L2 gene expression in human pancreatic cells. Molecular Biology Reports 36:8, 2329-2332
CrossRef74
Sarah E. Gollust, Paula M. Lantz. (2009) Communicating population health: Print news media coverage of type 2 diabetes. Social Science & Medicine 69:7, 1091-1098
CrossRef75
S. M. Blackman, S. Hsu, S. E. Ritter, K. M. Naughton, F. A. Wright, M. L. Drumm, M. R. Knowles, G. R. Cutting. (2009) A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 52:9, 1858-1865
CrossRef76
Stephanie-May Ruchat, Cathy E. Elks, Ruth J. F. Loos, Marie-Claude Vohl, S. John Weisnagel, Tuomo Rankinen, Claude Bouchard, Louis Pérusse. (2009) Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies. Acta Diabetologica 46:3, 217-226
CrossRef77
J. Szendrödi, B. Rose, N.C. Schloot, M. Roden. (2009) Aktuelles zu den molekularen Grundlagen der Ernährung. Der Diabetologe 5:6, 432-441
CrossRef78
J. M. García-Martínez, A. Chocarro-Calvo, C. M. Moya, C. García-Jiménez. (2009) WNT/β-catenin increases the production of incretins by entero-endocrine cells. Diabetologia 52:9, 1913-1924
CrossRef79
Elliot S. Stolerman, Jose C. Florez. (2009) Genomics of type 2 diabetes mellitus: implications for the clinician. Nature Reviews Endocrinology 5:8, 429-436
CrossRef80
Airani Sathananthan, Adrian Vella. (2009) Personalized pharmacotherapy for Type 2 diabetes mellitus. Personalized Medicine 6:4, 417-422
CrossRef81
K. Pilgaard, C. B. Jensen, J. H. Schou, V. Lyssenko, L. Wegner, C. Brøns, T. Vilsbøll, T. Hansen, S. Madsbad, J. J. Holst, A. Vølund, P. Poulsen, L. Groop, O. Pedersen, A. A. Vaag. (2009) The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 52:7, 1298-1307
CrossRef82
T J Wilkin. (2009) The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. International Journal of Obesity 33:7, 716-726
CrossRef83
T. Sparsø, N. Grarup, C. Andreasen, A. Albrechtsen, J. Holmkvist, G. Andersen, T. Jørgensen, K. Borch-Johnsen, A. Sandbæk, T. Lauritzen, S. Madsbad, T. Hansen, O. Pedersen. (2009) Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene–gene interaction. Diabetologia 52:7, 1308-1314
CrossRef84
E. R. Pearson. (2009) Translating TCF7L2: from gene to function. Diabetologia 52:7, 1227-1230
CrossRef85
N. Stefan, A. Fritsche, H.-U. Häring. (2009) Individualisierte Prävention des Typ-2-Diabetes. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 52:7, 677-682
CrossRef86
Bryan T. MacDonald, Keiko Tamai, Xi He. (2009) Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases. Developmental Cell 17:1, 9-26
CrossRef87
Ming-Hsi Wang, Kathy J. Helzlsouer, Michael W. Smith, Judith A. Hoffman-Bolton, Sandra L. Clipp, Viktoriya Grinberg, Angelo M. De Marzo, William B. Isaacs, Charles G. Drake, Yin Yao Shugart, Elizabeth A. Platz. (2009) Association of IL10 and Other immune response- and obesity-related genes with prostate cancer in CLUE II. The Prostate 69:8, 874-885
CrossRef88
S. A. Schäfer, K. Müssig, H. Staiger, F. Machicao, N. Stefan, B. Gallwitz, H. U. Häring, A. Fritsche. (2009) A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 52:6, 1075-1082
CrossRef89
E. S. Stolerman, A. K. Manning, J. B. McAteer, C. S. Fox, J. Dupuis, J. B. Meigs, J. C. Florez. (2009) TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study. Diabetologia 52:4, 614-620
CrossRef90
Ewan R. Pearson. (2009) Pharmacogenetics in diabetes. Current Diabetes Reports 9:2, 172-181
CrossRef91
J. B. Meigs. (2009) Prediction of type 2 diabetes: the dawn of polygenetic testing for complex disease. Diabetologia 52:4, 568-570
CrossRef92
Valeriya Lyssenko, Leif Groop. (2009) Genome-wide association study for type 2 diabetes: clinical applications. Current Opinion in Lipidology 20:2, 87-91
CrossRef93
William M. McClellan, Scott G. Satko, Elisa Gladstone, Jenna O. Krisher, Andrew S. Narva, Barry I. Freedman. (2009) Individuals With a Family History of ESRD Are a High-Risk Population for CKD: Implications for Targeted Surveillance and Intervention Activities. American Journal of Kidney Diseases 53:3, S100-S106
CrossRef94
Dharambir K Sanghera, Latonya Been, Lyda Ortega, Gurpreet S Wander, Narinder K Mehra, Christopher E Aston, John J Mulvihill, Sarju Ralhan. (2009) Testing the association of novel meta-analysis-derived diabetes risk genes with type II diabetes and related metabolic traits in Asian Indian Sikhs. Journal of Human Genetics 54:3, 162-168
CrossRef95
Eva Fisher, Heiner Boeing, Andreas Fritsche, Frank Doering, Hans-Georg Joost, Matthias B. Schulze. (2009) Whole-grain consumption and transcription factor-7-like 2 ( TCF7L2) rs7903146: gene–diet interaction in modulating type 2 diabetes risk. British Journal of Nutrition 101:04, 470
CrossRef96
Jean-Philippe Rey, Debra L. Ellies. (2009) Wnt modulators in the biotech pipeline. Developmental Dynamicsn/a-n/a
CrossRef97
Martin Armstrong, Christina Bromley, Nadine Cohen, Christine M Hunt, Robert O’Neill, Aidan Power. (2009) Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV – Breakout Session 1. Pharmacogenomics 10:1, 117-125
CrossRef98
Zhi-Qiang Du, Bin Fan, Xia Zhao, Randy Amoako, Max F. Rothschild. (2008) Association Analyses Between Type 2 Diabetes Genes and Obesity Traits in Pigs. Obesity
CrossRef99
Nicholas J. Wareham, Elizabeth H. Young, Ruth J.F. Loos. (2008) Epidemiological Study Designs to Investigate Gene–Behavior Interactions in the Context of Human Obesity. Obesity 16, S66-S71
CrossRef100
Nola M. Ries, David Castle. (2008) Nutrigenomics and Ethics Interface: Direct-to-Consumer Services and Commercial Aspects. OMICS: A Journal of Integrative Biology 12:4, 245-250
CrossRef101
Alan R. Shuldiner. (2008) Obesity Genes and Gene–Environment–Behavior Interactions: Recommendations for a Way Forward. Obesity 16, S79-S81
CrossRef102
Craig H. Warden, Janis S. Fisler. (2008) Gene–Nutrient and Gene–Physical Activity Summary—Genetics Viewpoint. Obesity 16, S55-S59
CrossRef103
Tanya Agurs-Collins, Muin J. Khoury, Denise Simon-Morton, Deborah H. Olster, Jennifer R. Harris, John A. Milner. (2008) Public Health Genomics: Translating Obesity Genomics Research Into Population Health Benefits. Obesity 16, S85-S94
CrossRef104
Meigs, James B., Shrader, Peter, Sullivan, Lisa M., McAteer, Jarred B., Fox, Caroline S., Dupuis, Josée, Manning, Alisa K., Florez, Jose C., Wilson, Peter W.F., D'Agostino, Ralph B. Sr., Cupples, L. Adrienne, . (2008) Genotype Score in Addition to Common Risk Factors for Prediction of Type 2 Diabetes. New England Journal of Medicine 359:21, 2208-2219
Full Text105
D. Altshuler, M. J. Daly, E. S. Lander. (2008) Genetic Mapping in Human Disease. Science 322:5903, 881-888
CrossRef106
J. L. González-Sánchez, M. T. Martínez-Larrad, C. Zabena, M. Pérez-Barba, M. Serrano-Ríos. (2008) Association of variants of the TCF7L2 gene with increases in the risk of type 2 diabetes and the proinsulin:insulin ratio in the Spanish population. Diabetologia 51:11, 1993-1997
CrossRef107
T. Jin. (2008) The WNT signalling pathway and diabetes mellitus. Diabetologia 51:10, 1771-1780
CrossRef108
T Reinehr, S Friedel, T D Mueller, A M Toschke, J Hebebrand, A Hinney. (2008) Evidence for an influence of TCF7L2 polymorphism rs7903146 on insulin resistance and sensitivity indices in overweight children and adolescents during a lifestyle intervention. International Journal of Obesity 32:10, 1521-1524
CrossRef109
Peter Kovacs, Janin Berndt, Karen Ruschke, Nora Klöting, Michael R. Schön, Antje Körner, Michael Stumvoll, Matthias Blüher. (2008) TCF7L2 gene expression in human visceral and subcutaneous adipose tissue is differentially regulated but not associated with type 2 diabetes mellitus. Metabolism 57:9, 1227-1231
CrossRef110
Alessandro Doria, Mary-Elizabeth Patti, C. Ronald Kahn. (2008) The Emerging Genetic Architecture of Type 2 Diabetes. Cell Metabolism 8:3, 186-200
CrossRef111
Jeff Gulcher, Kari Stefansson. (2008) The clinical utility of genetic risk variants in type 2 diabetes. Expert Opinion on Medical Diagnostics 2:8, 991-1002
CrossRef112
F. Iris, M. Gea, P. -H. Lampe, G. Dine, P. Santamaria. (2008) Integrative biology in the discovery of relevant biomarkers monitoring cognitive disorders pathogenesis and progression. Bio Tribune Magazine 28:1, 8-23
CrossRef113
A. L. Gloyn, M. I. McCarthy. (2008) Genetics: how the UKPDS contributed to determining the genetic landscape of Type 2 diabetes. Diabetic Medicine 25, 35-40
CrossRef114
Jill P Crandall, William C Knowler, Steven E Kahn, David Marrero, Jose C Florez, George A Bray, Steven M Haffner, Mary Hoskin, David M Nathan. (2008) The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology & Metabolism 4:7, 382-393
CrossRef115
Haruhiko Osawa, Kazuya Yamada, Yasuharu Tabara, Masaaki Ochi, Hiroshi Onuma, Wataru Nishida, Ikki Shimizu, Ryuichi Kawamoto, Yasuhisa Fujii, Tetsuro Miki, Jun Ohashi, Hideichi Makino. (2008) The G/G genotype of a single nucleotide polymorphism at –1066 of c-Jun N-terminal kinase 1 gene (MAPK8) does not affect type 2 diabetes susceptibility despite the specific binding of AP2α. Clinical Endocrinology 69:1, 36-44
CrossRef116
Valeriya Lyssenko. (2008) The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update. Current Opinion in Clinical Nutrition and Metabolic Care 11:4, 385-392
CrossRef117
D. K. Sanghera, S. K. Nath, L. Ortega, M. Gambarelli, X. Kim-Howard, J. R. Singh, S. K. Ralhan, G. S. Wander, N. K. Mehra, J. J. Mulvihill, M. I. Kamboh. (2008) TCF7L2 Polymorphisms are Associated with Type 2 Diabetes in Khatri Sikhs from North India: Genetic Variation Affects Lipid Levels. Annals of Human Genetics 72:4, 499-509
CrossRef118
J. C. Florez. (2008) Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes?. Diabetologia 51:7, 1100-1110
CrossRef119
Hussein Saadi, Nicolaas Nagelkerke, S. George Carruthers, Sheela Benedict, Samar Abdulkhalek, Richard Reed, Miodrag Lukic, M. Gary Nicholls. (2008) Association of TCF7L2 polymorphism with diabetes mellitus, metabolic syndrome, and markers of beta cell function and insulin resistance in a population-based sample of Emirati subjects. Diabetes Research and Clinical Practice 80:3, 392-398
CrossRef120
David Seo, Pascal J. Goldschmidt-Clermont. (2008) Cardiovascular Genetic Medicine: The Genetics of Coronary Heart Disease. Journal of Cardiovascular Translational Research 1:2, 166-170
CrossRef121
Mary Beth Weber, K.M. Venkat Narayan. (2008) Preventing type 2 diabetes: Genes or lifestyle?. Primary Care Diabetes 2:2, 65-66
CrossRef122
Maja Ahlzén, Lovisa E. Johansson, Camilla Cervin, Hans Tornqvist, Leif Groop, Martin Ridderstråle. (2008) Expression of the transcription factor 7-like 2 gene (TCF7L2) in human adipocytes is down regulated by insulin. Biochemical and Biophysical Research Communications 370:1, 49-52
CrossRef123
Adrian Vella, Michael Camilleri. (2008) Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert Opinion on Pharmacotherapy 9:7, 1109-1119
CrossRef124
R Sarzani, F Salvi, M Bordicchia, F Pietrucci, D Caraceni, L Lancioni, P Dessí-Fulgheri, A Rappelli. (2008) TCF7L2 alleles and metabolic syndrome in non-diabetic obese hypertensive patients. Journal of Human Hypertension 22:5, 373-375
CrossRef125
Michael A Pacanowski, Charles W Hopley, Christina L Aquilante. (2008) Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opinion on Drug Metabolism & Toxicology 4:5, 529-544
CrossRef126
Stéphane Cauchi, Philippe Froguel. (2008) TCF7L2 genetic defect and type 2 diabetes. Current Diabetes Reports 8:2, 149-155
CrossRef127
Lu Qi. (2008) Genetic effects, gene-lifestyle interactions, and type 2 diabetes. Central European Journal of Medicine 3:1, 1-7
CrossRef128
J.-F. Gautier, S.-P. Choukem, J. Girard. (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metabolism 34, S65-S72
CrossRef129
Liam R. Brunham, Janine K. Kruit, C. Bruce Verchere, Michael R. Hayden. (2008) Cholesterol in islet dysfunction and type 2 diabetes. Journal of Clinical Investigation 118:2, 403-408
CrossRef130
Allan F. Moore, Jose C. Florez. (2008) Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic Therapy. Annual Review of Medicine 59:1, 95-111
CrossRef131
Kazuaki Miyake, Yukio Horikawa, Kazuo Hara, Kazuki Yasuda, Haruhiko Osawa, Hiroto Furuta, Yushi Hirota, Kazuya Yamagata, Yoshinori Hinokio, Yoshitomo Oka, Naoko Iwasaki, Yasuhiko Iwamoto, Yuichiro Yamada, Yutaka Seino, Hiroshi Maegawa, Atsunori Kashiwagi, Ken Yamamoto, Katsushi Tokunaga, Jun Takeda, Hideichi Makino, Kishio Nanjo, Takashi Kadowaki, Masato Kasuga. (2008) Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. Journal of Human Genetics 53:2, 174-180
CrossRef132
Stéphane Cauchi, Hélène Choquet, Ruth Gutiérrez-Aguilar, Frédéric Capel, Katrine Grau, Christine Proença, Christian Dina, Alex Duval, Beverley Balkau, Michel Marre, Natascha Potoczna, Dominique Langin, Fritz Horber, Thorkild I.A. Sørensen, Guillaume Charpentier, David Meyre, Philippe Froguel. (2008) Effects of TCF7L2 Polymorphisms on Obesity in European Populations. Obesity 16:2, 476-482
CrossRef133
Olga A. Iakoubova, Marc S. Sabatine, Charles M. Rowland, Carmen H. Tong, Joseph J. Catanese, Koustubh Ranade, Katy L. Simonsen, Todd G. Kirchgessner, Christopher P. Cannon, James J. Devlin, Eugene Braunwald. (2008) Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes. Journal of the American College of Cardiology 51:4, 449-455
CrossRef134
V.S. Kashyap. (2008) TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program. Yearbook of Vascular Surgery 2008, 3-4
CrossRef135
Olivia Gill-Carey, Andrew T Hattersley. (2007) Genetics and type 2 diabetes in youth. Pediatric Diabetes 8:s9, 42-47
CrossRef136
S. Schinner, F. Ülgen, C. Papewalis, M. Schott, A. Woelk, A. Vidal-Puig, W. A. Scherbaum. (2007) Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules. Diabetologia 51:1, 147-154
CrossRef137
S. A. Schäfer, O. Tschritter, F. Machicao, C. Thamer, N. Stefan, B. Gallwitz, J. J. Holst, J. M. Dekker, L. M. t’Hart, G. Nijpels, T. W. Haeften, H. U. Häring, A. Fritsche. (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:12, 2443-2450
CrossRef138
M. A. Nauck, J. J. Meier. (2007) The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. Diabetologia 50:12, 2413-2416
CrossRef139
M. Horikoshi, K. Hara, C. Ito, N. Shojima, R. Nagai, K. Ueki, P. Froguel, T. Kadowaki. (2007) Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population. Diabetologia 50:12, 2461-2466
CrossRef140
Manal F. Abdelmalek, Anna Mae Diehl. (2007) Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance. Medical Clinics of North America 91:6, 1125-1149
CrossRef141
M. N. Weedon. (2007) The importance of TCF7L2. Diabetic Medicine 24:10, 1062-1066
CrossRef142
Wendy K. Chung. (2007) Implementation of Genetics to Personalize Medicine. Gender Medicine 4:3, 248-265
CrossRef143
Yen Ling Low, E. Shyong Tai. (2007) Understanding diet-gene interactions: Lessons from studying nutrigenomics and cardiovascular disease. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 622:1-2, 7-13
CrossRef144
Dhanasekaran Bodhini, Venkatesan Radha, Monalisa Dhar, Nagarajan Narayani, Viswanathan Mohan. (2007) The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians. Metabolism 56:9, 1174-1178
CrossRef145
A. Dahlgren, B. Zethelius, K. Jensevik, A.-C. Syvänen, C. Berne. (2007) Variants of the TCF7L2 gene are associated with beta cell dysfunction and confer an increased risk of type 2 diabetes mellitus in the ULSAM cohort of Swedish elderly men. Diabetologia 50:9, 1852-1857
CrossRef146
Robert N. Baldassano, Jonathan P. Bradfield, Dimitri S. Monos, Cecilia E. Kim, Joseph T. Glessner, Tracy Casalunovo, Edward C. Frackelton, F. George Otieno, Stathis Kanterakis, Julie L. Shaner, Ryan M. Smith, Andrew W. Eckert, Luke J. Robinson, Chioma C. Onyiah, Debra J. Abrams, Rosetta M. Chiavacci, Robert Skraban, Marcella Devoto, Struan F.A. Grant, Hakon Hakonarson. (2007) Association of Variants of the Interleukin-23 Receptor Gene With Susceptibility to Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 5:8, 972-976
CrossRef147
Valeriya Lyssenko, Roberto Lupi, Piero Marchetti, Silvia Del Guerra, Marju Orho-Melander, Peter Almgren, Marketa Sjögren, Charlotte Ling, Karl-Fredrik Eriksson, υsa-Linda Lethagen, Rita Mancarella, Göran Berglund, Tiinamaija Tuomi, Peter Nilsson, Stefano Del Prato, Leif Groop. (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. Journal of Clinical Investigation 117:8, 2155-2163
CrossRef148
Andrew T. Hattersley. (2007) Prime suspect: the TCF7L2 gene and type 2 diabetes risk. Journal of Clinical Investigation 117:8, 2077-2079
CrossRef149
Martijn van de Bunt, Anna L Gloyn. (2007) Monogenic disorders of the pancreatic β-cell: personalizing treatment for rare forms of diabetes and hypoglycemia. Personalized Medicine 4:3, 247-259
CrossRef150
S. C. Elbein, W. S. Chu, S. K. Das, A. Yao-Borengasser, S. J. Hasstedt, H. Wang, N. Rasouli, P. A. Kern. (2007) Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia 50:8, 1621-1630
CrossRef151
A. Fritsche, C. Thamer, N. Stefan, H.-U. Häring. (2007) Gen-Umwelt-Interaktion in Pathogenese und Prävention des Diabetes mellitus Typ 2. Der Internist 48:7, 669-675
CrossRef152
Steven C Elbein. (2007) Evaluation of polymorphisms known to contribute to risk for diabetes in African and African???American populations. Current Opinion in Clinical Nutrition and Metabolic Care 10:4, 415-419
CrossRef153
T. M. Frayling. (2007) A new era in finding Type 2 diabetes genes?the unusual suspects.. Diabetic Medicine 24:7, 696-701
CrossRef154
Niels Grarup, Gitte Andersen. (2007) Gene???environment interactions in the pathogenesis of type 2 diabetes and metabolism. Current Opinion in Clinical Nutrition and Metabolic Care 10:4, 420-426
CrossRef155
Jose C Florez. (2007) The new type 2 diabetes gene TCF7L2. Current Opinion in Clinical Nutrition and Metabolic Care 10:4, 391-396
CrossRef156
Struan FA Grant, Hakon Hakonarson. (2007) Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Review of Molecular Diagnostics 7:4, 371-393
CrossRef157
Markku Laakso. (2007) Challenges in studies of the genetic basis of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 2:4, 451-459
CrossRef158
Stéphane Cauchi, Younes Achhab, Hélène Choquet, Christian Dina, Franz Krempler, Raimund Weitgasser, Chakib Nejjari, Wolfgang Patsch, Mohamed Chikri, David Meyre, Philippe Froguel. (2007) TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. Journal of Molecular Medicine 85:7, 777-782
CrossRef159
Katharine R Owen, Mark I McCarthy. (2007) Genetics of type 2 diabetes. Current Opinion in Genetics & Development 17:3, 239-244
CrossRef160
B.O. Böhm, C. C. Polychronakos. (2007) Neues zur Genetik des Diabetes mellitus Typ 2. Der Diabetologe 3:3, 211-220
CrossRef161
Rachel M. Freathy, Michael N. Weedon, Amanda Bennett, Elina Hyppönen, Caroline L. Relton, Beatrice Knight, Beverley Shields, Kirstie S. Parnell, Christopher J. Groves, Susan M. Ring, Marcus E. Pembrey, Yoav Ben-Shlomo, David P. Strachan, Chris Power, Marjo-Riitta Jarvelin, Mark I. McCarthy, George Davey Smith, Andrew T. Hattersley, Timothy M. Frayling. (2007) Type 2 Diabetes TCF7L2 Risk Genotypes Alter Birth Weight: A Study of 24,053 Individuals. The American Journal of Human Genetics 80:6, 1150-1161
CrossRef162
J. Wang, J. Kuusisto, M. Vänttinen, T. Kuulasmaa, J. Lindström, J. Tuomilehto, M. Uusitupa, M. Laakso. (2007) Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 50:6, 1192-1200
CrossRef163
C. H. Kimber, A. S. F. Doney, E. R. Pearson, M. I. McCarthy, A. T. Hattersley, G. P. Leese, A. D. Morris, C. N. A. Palmer. (2007) TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia 50:6, 1186-1191
CrossRef164
Scott G. Satko, John R. Sedor, Sudha K. Iyengar, Barry I. Freedman. (2007) Familial Clustering of Chronic Kidney Disease. Seminars in Dialysis 20:3, 229-236
CrossRef165
Marc L. Reitman, Eric E. Schadt. (2007) Pharmacogenetics of metformin response: a step in the path toward personalized medicine. Journal of Clinical Investigation 117:5, 1226-1229
CrossRef166
N. Shaat, Å. Lernmark, E. Karlsson, S. Ivarsson, H. Parikh, K. Berntorp, L. Groop. (2007) A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus. Diabetologia 50:5, 972-979
CrossRef167
T. Hayashi, Y. Iwamoto, K. Kaku, H. Hirose, S. Maeda. (2007) Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population. Diabetologia 50:5, 980-984
CrossRef168
EJ Parra, E Cameron, L Simmonds, A Valladares, P McKeigue, M Shriver, N Wacher, J Kumate, R Kittles, M Cruz. (2007) Association of TCF7L2 polymorphisms with type 2 diabetes in Mexico City. Clinical Genetics 71:4, 359-366
CrossRef169
M. Horikoshi, K. Hara, C. Ito, R. Nagai, P. Froguel, T. Kadowaki. (2007) A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 50:4, 747-751
CrossRef170
Michèle M Sale, Stephen S Rich. (2007) Genetic contributions to Type 2 diabetes: recent insights. Expert Review of Molecular Diagnostics 7:2, 207-217
CrossRef171
Olle Melander. (2007) Are minor gene effects of clinical importance?. Journal of Hypertension 25:3, 505-507
CrossRef172
Sudha K. Iyengar, Sharon G. Adler. (2007) The Application of the HapMap to Diabetic Nephropathy and Other Causes of Chronic Renal Failure. Seminars in Nephrology 27:2, 223-236
CrossRef173
Sofia Mayans, Kurt Lackovic, Petter Lindgren, Karin Ruikka, Åsa Ågren, Mats Eliasson, Dan Holmberg. (2007) TCF7L2 polymorphisms are associated with type 2 diabetes in northern Sweden. European Journal of Human Genetics 15:3, 342-346
CrossRef174
Robert Sladek, Ghislain Rocheleau, Johan Rung, Christian Dina, Lishuang Shen, David Serre, Philippe Boutin, Daniel Vincent, Alexandre Belisle, Samy Hadjadj, Beverley Balkau, Barbara Heude, Guillaume Charpentier, Thomas J. Hudson, Alexandre Montpetit, Alexey V. Pshezhetsky, Marc Prentki, Barry I. Posner, David J. Balding, David Meyre, Constantin Polychronakos, Philippe Froguel. (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:7130, 881-885
CrossRef175
Agnar Helgason, Snæbjörn Pálsson, Gudmar Thorleifsson, Struan F A Grant, Valur Emilsson, Steinunn Gunnarsdottir, Adebowale Adeyemo, Yuanxiu Chen, Guanjie Chen, Inga Reynisdottir, Rafn Benediktsson, Anke Hinney, Torben Hansen, Gitte Andersen, Knut Borch-Johnsen, Torben Jorgensen, Helmut Schäfer, Mezbah Faruque, Ayo Doumatey, Jie Zhou, Robert L Wilensky, Muredach P Reilly, Daniel J Rader, Yu Bagger, Claus Christiansen, Gunnar Sigurdsson, Johannes Hebebrand, Oluf Pedersen, Unnur Thorsteinsdottir, Jeffrey R Gulcher, Augustine Kong, Charles Rotimi, Kári Stefánsson. (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nature Genetics 39:2, 218-225
CrossRef176
Peter Weyrich, Norbert Stefan, Hans-Ulrich Häring, Markku Laakso, Andreas Fritsche. (2007) Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. Journal of Molecular Medicine 85:2, 107-117
CrossRef177
Daniel J. Drucker. (2007) The role of gut hormones in glucose homeostasis. Journal of Clinical Investigation 117:1, 24-32
CrossRef178
Clara C. Elbers, N. Charlotte Onland-Moret, Lude Franke, Anne G. Niehoff, Yvonne T. van der Schouw, Cisca Wijmenga. (2007) A strategy to search for common obesity and type 2 diabetes genes. Trends in Endocrinology & Metabolism 18:1, 19-26
CrossRef179
H H Karnib, S Chua, A G Gharavi. (2007) Genes for diabetic nephropathy: Sweet prospects on the horizon. Kidney International 71:2, 94-96
CrossRef180
S. Cauchi, M. Vaxillaire, H. Choquet, E. Durand, A. Duval, M. Polak, P. Froguel. (2006) No major contribution of TCF7L2 sequence variants to maturity onset of diabetes of the young (MODY) or neonatal diabetes mellitus in French white subjects. Diabetologia 50:1, 214-216
CrossRef181
E. Zeggini, M. I. McCarthy. (2006) TCF7L2: the biggest story in diabetes genetics since HLA?. Diabetologia 50:1, 1-4
CrossRef182
S. F. Field, J. M. M. Howson, D. J. Smyth, N. M. Walker, D. B. Dunger, J. A. Todd. (2006) Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia 50:1, 212-213
CrossRef183
Manal F. Abdelmalek, Anna Mae Diehl. (2006) Mechanisms underlying nonalcoholic steatohepatitis. Drug Discovery Today: Disease Mechanisms 3:4, 479-488
CrossRef184
Friedrich C. Luft. (2006) A high mobility group box-containing transcription factor leads to diabetes risk. Journal of Molecular Medicine 84:12, 985-987
CrossRef185
O'Rahilly, Stephen, Wareham, Nicholas J., . (2006) Genetic Variants and Common Diseases — Better Late Than Never. New England Journal of Medicine 355:3, 306-308
Full Text
